Teva (NYSE: TEVA) EVP sells 18,600 shares in planned trade

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that executive Evan Lippman, EVP, Business Development, sold 18,600 Ordinary Shares on August 17, 2026. The shares, which may be represented by American Depositary Shares on a one-for-one basis, were sold at a weighted average price of $36.5748, with individual trades between $36.57 and $36.61. After this sale, Lippman directly holds 25,591 Ordinary Shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on May 16, 2026, indicating it followed a pre-established trading schedule.

Insider Trade Summary 10b5-1

Net Seller: 18,600 shares

Net Sell 1 txn

Insider Lippman Evan

Role EVP, Business Development

Sold 18,600 shs ($680K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2, F3	18,600	$36.5748	$680K

Holdings After Transaction: Ordinary Shares — 25,591 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 18,600 shares Weighted average sale price: $36.5748 per share Sale price range: $36.57–$36.61 per share +2 more

5 metrics

Shares sold 18,600 shares Ordinary Shares sold by Evan Lippman on August 17, 2026

Weighted average sale price $36.5748 per share Average price for the 18,600 Ordinary Shares sold

Sale price range $36.57–$36.61 per share Range of prices for multiple transactions comprising the sale

Shares held after transaction 25,591 shares Direct Ordinary Share holdings of Evan Lippman following the sale

Rule 10b5-1 plan adoption date May 16, 2026 Date Lippman adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, American Depositary Shares, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transaction did TEVA executive Evan Lippman report on this Form 4 for TEVA?

Evan Lippman, EVP, Business Development at TEVA, sold 18,600 Ordinary Shares on August 17, 2026. The sale was reported as a direct ownership transaction and executed under a Rule 10b5-1 trading plan adopted on May 16, 2026.

At what price did Evan Lippman sell TEVA shares in this reported transaction?

The reported weighted average price was $36.5748 per TEVA Ordinary Share. According to the filing, the shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, and detailed trade-level pricing is available upon request from specified parties.

How many TEVA shares does Evan Lippman hold after the August 17, 2026 sale?

Following the sale, Evan Lippman directly holds 25,591 TEVA Ordinary Shares. This post-transaction holding reflects his remaining direct equity position in TEVA after disposing of 18,600 shares in the reported transaction.

Was the TEVA insider sale by Evan Lippman made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted on May 16, 2026, indicating the sale followed a pre-arranged schedule rather than being timed at the insider’s discretion.

What is the relationship between TEVA Ordinary Shares and American Depositary Shares (ADSs)?

The filing explains that TEVA’s Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one Ordinary Share, providing U.S. investors a way to hold TEVA’s equity through ADSs.

How many TEVA shares in total did Evan Lippman sell in this Form 4 filing?

The Form 4 reports that Evan Lippman sold 18,600 TEVA Ordinary Shares. These shares were sold in multiple trades on August 17, 2026, at prices between $36.57 and $36.61, producing a weighted average sale price of $36.5748 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 04:01 PM Accepted by SEC EDGAR 08/19/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippman Evan

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/17/2026		S(2)		18,600	D	$36.5748(3)	25,591	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Dov Bergwerk as attorney-in-fact for Evan Lippman	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)